Investors and analysts alike expect GlaxoSmithKline ($GSK) to increase its bid for Human Genome Sciences ($HGSI), but not by much, Bloomberg reports. GSK probably will raise its $2.6 billion, $13-per-share offer by $1 to $2 per share, they said. Report